Increased levels of PD-L1 on circulating exosomes was exhibited by clinical responders within 3 to 6 weeks of therapy, which suggested a positive correlation of PD-L1 levels to T cell rejuvenation and successful induction of anti-tumor immunity by anti-PD1 therapy [45]. Here, CD274 is linked to neoplasm.